dimethyl-fumarate-nrf2-ad-nct06850597

Migration, Crosslink

📖

dimethyl-fumarate-nrf2-ad-nct06850597

active

wiki page Created: 2026-04-02T07:19:04 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-clinical-trials-dimethyl-fumarate-n

📖 Wiki Page

clinical_trial4373 wordssynced 2026-04-02

Dimethyl Fumarate Phase 2 - Nrf2 Activation for Alzheimer's Disease (NCT06850597)

Overview

This Phase 2 clinical trial investigates dimethyl fumarate (DMF), an established multiple sclerosis drug with potent Nrf2-activating properties, as a potential disease-modifying treatment for Alzheimer's disease. The trial represents a drug repurposing approach, taking advantage of the well-characterized safety profile of DMF (marketed as Tecfidera for multiple sclerosis) to target neuroprotective pathways via Nrf2 transcription factor activation in AD[@nct].

The study addresses a critical gap in AD therapeutics by targeting the oxidative stress and neuroinflammation components of the disease that are not addressed by current amyloid-targeting approaches. Oxidative stress is one of the earliest detectable pathological features in AD, and the Nrf2 pathway is the cell's primary defense mechanism against oxidative damage[@nrf22023].

Alzheimer's disease (AD) is the most common cause of dementia, affecting approximately 6.5 million Americans and 55 million people worldwide. The disease is characterized by progressive cognitive decline, with memory loss being the most prominent early symptom. Despite extensive research, no cure exists, and current treatments provide only modest symptomatic benefit. This has driven interest in drug repurposing—identifying existing drugs with mechanisms that may address AD pathology.

...

Dimethyl Fumarate Phase 2 - Nrf2 Activation for Alzheimer's Disease (NCT06850597)

Overview

This Phase 2 clinical trial investigates dimethyl fumarate (DMF), an established multiple sclerosis drug with potent Nrf2-activating properties, as a potential disease-modifying treatment for Alzheimer's disease. The trial represents a drug repurposing approach, taking advantage of the well-characterized safety profile of DMF (marketed as Tecfidera for multiple sclerosis) to target neuroprotective pathways via Nrf2 transcription factor activation in AD[@nct].

The study addresses a critical gap in AD therapeutics by targeting the oxidative stress and neuroinflammation components of the disease that are not addressed by current amyloid-targeting approaches. Oxidative stress is one of the earliest detectable pathological features in AD, and the Nrf2 pathway is the cell's primary defense mechanism against oxidative damage[@nrf22023].

Alzheimer's disease (AD) is the most common cause of dementia, affecting approximately 6.5 million Americans and 55 million people worldwide. The disease is characterized by progressive cognitive decline, with memory loss being the most prominent early symptom. Despite extensive research, no cure exists, and current treatments provide only modest symptomatic benefit. This has driven interest in drug repurposing—identifying existing drugs with mechanisms that may address AD pathology.

Dimethyl fumarate represents a compelling candidate for repurposing due to its established safety profile in multiple sclerosis, its ability to activate the Nrf2 pathway (which is dysregulated in AD), and its anti-inflammatory properties. The Medical University of Lodz in Poland is conducting this Phase 2 trial to evaluate whether DMF can slow cognitive decline in patients with mild-to-moderate AD.

Pathway / Mechanism Diagram

Mermaid diagram (expand to render)

Oxidative Stress in Alzheimer's Disease

Role of Oxidative Damage

Oxidative stress is recognized as a central pathological feature of Alzheimer's disease, with evidence of oxidative damage present even in early disease stages. The brain is particularly vulnerable to oxidative damage due to:

High oxygen consumption (20% of body oxygen despite 2% of body weight)
High lipid content (DHA, which is highly susceptible to peroxidation)
Limited antioxidant capacity compared to other organs
High mitochondrial density generating reactive oxygen species (ROS)

In AD, multiple sources of oxidative stress converge:

Mitochondrial Dysfunction:

Electron transport chain complexes I and IV show reduced activity
Increased mitochondrial DNA mutations in AD brain
Impaired calcium buffering leads to ROS generation
Mitochondrial permeability transition pore opening

Metal Homeostasis:

Iron, copper, and zinc accumulate in AD brain
Transition metals catalyze Fenton reactions generating hydroxyl radicals
Amyloid-beta interacts with metals, promoting oxidation

Inflammation-Associated ROS:

Activated microglia produce ROS and reactive nitrogen species
NADPH oxidase activation in glial cells
Cytokine-induced oxidative burst

Advanced Glycation End Products (AGEs):

Glucose oxidation products accumulate in AD brain
AGEs cross-link proteins, forming age pigment
RAGE receptor engagement promotes inflammation

Evidence of Oxidative Damage in AD

Multiple biomarkers demonstrate oxidative stress in AD:

| Biomarker | Change in AD | Source |
|-----------|--------------|--------|
| 8-OHdG (DNA oxidation) | Increased | Brain tissue, CSF, urine |
| 4-HNE (lipid peroxidation) | Increased | Brain tissue, plasma |
| 8-iso-PGF2α (lipid peroxidation) | Increased | Plasma, urine |
| Protein carbonyls | Increased | Brain tissue, plasma |
| GSH/GSSG ratio | Decreased | Brain tissue, CSF |
| SOD activity | Variable | Brain tissue |

This oxidative damage correlates with cognitive decline and disease severity, making antioxidant pathways attractive therapeutic targets.

The Nrf2 Pathway

Nrf2 Biology

Nuclear factor erythroid 2-related factor 2 (Nrf2) is a master regulator of cellular defense against oxidative stress. This transcription factor controls the expression of over 200 genes involved in antioxidant responses, xenobiotic metabolism, and cellular protection.

Nrf2 Structure and Function:
Nrf2 is a basic leucine zipper transcription factor encoded by the NFE2L2 gene. It contains seven highly conserved domains (Neh1-7), each with distinct functions:

Neh1: DNA binding and dimerization with small Maf proteins
Neh2: Transactivation domain containing Keap1 interaction sites
Neh3-6: Transactivation domains
Neh7: Interaction with other transcription factors

Regulation by Keap1:
Under basal conditions, Nrf2 is sequestered in the cytoplasm by Keap1 (Kelch-like ECH-associated protein 1), which targets Nrf2 for ubiquitination and proteasomal degradation. Keap1 acts as a molecular sensor for oxidative stress, containing cysteine residues that are modified by electrophiles.

Activation Mechanism:

Oxidative stress or electrophiles modify Keap1 cysteine residues

Nrf2 escapes Keap1-mediated degradation

Nrf2 translocates to the nucleus

Nrf2 heterodimerizes with small Maf proteins

Complex binds to Antioxidant Response Element (ARE) in target gene promoters

Transcription of antioxidant and cytoprotective genes is induced

Nrf2 Target Genes

Nrf2 regulates a comprehensive network of protective genes:

Phase 2 Detoxification Enzymes:

NAD(P)H:quinone oxidoreductase 1 (NQO1)
Glutamate-cysteine ligase (GCL) - rate-limiting step in GSH synthesis
Glutathione S-transferases (GSTs)
UDP-glucuronosyltransferases (UGTs)
Sulfotransferases (SULTs)

Antioxidant Proteins:

Heme oxygenase-1 (HO-1)
Thioredoxin (Trx)
Thioredoxin reductase (TrxR)
Peroxiredoxins (Prxs)
Superoxide dismutases (SOD1, SOD2, SOD3)

Other Protective Proteins:

Multidrug resistance-associated proteins (MRPs)
Aldehyde dehydrogenases (ALDHs)
Autophagy proteins (p62/SQSTM1)

Nrf2 Dysfunction in AD

Multiple mechanisms contribute to Nrf2 impairment in AD:

Transcriptional Dysregulation:

Nrf2 nuclear translocation is reduced in AD brain
ARE-binding activity is diminished
Epigenetic silencing of NFE2L2 has been reported

Keap1 Overactivation:

Oxidative modifications of Keap1 in AD may dysregulate its function
p62 accumulation (common in AD) may sequester Keap1

Impaired Clearance:

Proteasomal degradation of Nrf2 may be enhanced
Nuclear export may be increased

Therapeutic Implication:
The "Nrf2 insufficiency" in AD creates a rationale for pharmacological Nrf2 activation. By enhancing Nrf2 activity, it may be possible to restore cellular antioxidant capacity and slow disease progression.

Mechanism of Action

Nrf2-ARE Pathway Activation

Dimethyl fumarate (DMF) exerts its neuroprotective effects primarily through Nrf2 pathway activation:

Covalent Modification: DMF and its metabolite monomethyl fumarate (MMF) covalently modify Keap1 cysteine residues (particularly C151), causing a conformational change

Nrf2 Release: Modified Keap1 can no longer efficiently target Nrf2 for degradation

Nuclear Translocation: Stabilized Nrf2 translocates to the nucleus

ARE Binding: Nrf2-Small Maf heterodimers bind to Antioxidant Response Elements

Gene Transcription: Upregulation of antioxidant, anti-inflammatory, and cytoprotective genes

The resulting gene expression changes include:

| Gene | Function | Benefit in AD |
|------|----------|----------------|
| NQO1 | Coenzyme Q10 regeneration | Mitochondrial protection |
| HO-1 | Heme degradation, anti-inflammatory | Neuroprotection |
| GCLM | Glutathione synthesis | Antioxidant capacity |
| SOD2 | Superoxide dismutase | Mitochondrial ROS scavenging |
| PRDX1 | Peroxide reduction | Oxidative stress reduction |
| NQO1 | Coenzyme Q10 regeneration | Energy metabolism |

Anti-inflammatory Effects

Beyond direct antioxidant effects, Nrf2 activation suppresses neuroinflammation:

Cytokine Suppression: Nrf2 inhibits NF-κB signaling, reducing IL-1β, TNF-α, IL-6
Microglial Modulation: Nrf2 promotes anti-inflammatory microglial phenotype
Inflammasome Inhibition: Nrf2 activation reduces NLRP3 inflammasome activation
T-cell Regulation: Nrf2 modulates adaptive immune responses

Amyloid Beta Modulation

Preclinical evidence suggests DMF may affect amyloid pathology:

Reduced Aβ-induced oxidative stress
Decreased amyloid precursor protein processing
Enhanced clearance of Aβ aggregates
Protection against Aβ-induced neurotoxicity

Mitochondrial Protection

Nrf2 activation protects mitochondria through:

Enhanced expression of mitochondrial antioxidants (SOD2, Prx3, Trx2)
Improved mitochondrial biogenesis (via PGC-1α cooperation)
Protection against mitochondrial permeability transition
Enhanced mitophagy

Rationale for Repurposing

Multiple Sclerosis Clinical Experience

Dimethyl fumarate (Tecfidera) received FDA approval for relapsing-remitting multiple sclerosis (RRMS) in 2013, providing extensive clinical experience:

Efficacy:

Reduced annualized relapse rate by 46% vs. placebo in DEFINE trial
Reduced disability progression by 38% vs. placebo
Significant reduction in MRI lesions

Safety Profile:

Well-characterized adverse event profile
Common events: flushing, gastrointestinal symptoms, lymphopenia
Rare serious events: progressive multifocal leukoencephalopathy (PML), severe liver injury
No increased malignancy risk with extended follow-up

Pharmacology:

Oral bioavailability
CNS penetration demonstrated
Metabolized to monomethyl fumarate (active metabolite)
Twice-daily dosing

AD-Specific Rationale

Alzheimer's disease shares pathological features with multiple sclerosis that DMF may address:

Oxidative Stress: Prominent in both conditions
Neuroinflammation: Central to MS and present in AD
Mitochondrial Dysfunction: Seen in both diseases
Blood-Brain Barrier: Impaired in both conditions

The Nrf2-activating properties of DMF are particularly relevant because:

Nrf2 is dysregulated in AD brain

Nrf2 target genes are reduced in AD

Enhancing Nrf2 may address multiple AD pathological features

Safety has been established in large MS population

This creates a strong rationale for testing DMF in AD.

Trial Design

Study Design

This is a randomized, double-blind, placebo-controlled, parallel-group Phase 2 trial:

Allocation: 1:1 randomization to DMF or placebo
Blinding: Double-blind (participants and investigators)
Duration: 48 weeks (12 months)
Setting: Single center (Medical University of Lodz, Poland)

Treatment Regimen

The dosing follows the approved MS regimen with adaptation:

Dimethyl Fumarate Arm:

Starting dose: 120 mg twice daily for 4 weeks (titration)
Maintenance: 240 mg twice daily
Total daily dose: 480 mg

Placebo Arm:

Matching tablets, same titration schedule

The titration period reduces flushing and GI side effects seen with rapid dose escalation.

Inclusion Criteria

Age 50-85 years
Diagnosis of probable Alzheimer's disease per NIA-AA criteria
MMSE score 18-26 (mild-to-moderate disease)
Amyloid positive (confirmed by PET or CSF biomarkers)
Stable on allowed AD medications (if applicable) for ≥8 weeks
Caregiver available to supervise treatment and attend assessments

Exclusion Criteria

Diagnosis of other dementia types (vascular, Lewy body, frontotemporal)
Significant psychiatric illness (depression, schizophrenia)
History of stroke or significant cerebrovascular disease
Current participation in other clinical trials
Prior DMF exposure
Contraindications to MRI
Liver disease, significant renal disease
Pregnancy or breastfeeding

Randomization and Stratification

Participants may be stratified by:

Disease severity (MMSE 18-22 vs. 23-26)
Concomitant AD medication use (yes/no)

This ensures balanced distribution of prognostic factors between arms.

Endpoints

Primary Endpoints

Change in ADAS-Cog (Alzheimer's Disease Assessment Scale-Cognitive subscale)

Timeframe: Baseline to Week 48
ADAS-Cog is the gold standard for measuring cognitive function in AD trials
11-item version ranges from 0-70, higher scores indicate worse function
Mean decline in placebo is approximately 4-6 points over 12 months

Safety and Tolerability

Adverse events (AEs), serious adverse events (SAEs)
Laboratory abnormalities (hematology, chemistry)
Discontinuation rates

Secondary Endpoints

Cerebrospinal Fluid Biomarkers

Aβ42 (amyloid)
Total tau (neurodegeneration)
Phosphorylated tau p-tau181 (tau pathology)
Nrf2 pathway activation markers (HO-1, NQO1)

Brain MRI Volumetry

Hippocampal volume change
Whole brain volume change
Ventricular enlargement

Functional Assessment

ADCS-ADL (Alzheimer's Disease Cooperative Study-Activities of Daily Living)
Clinical Dementia Rating Sum of Boxes (CDR-SB)

Nrf2 Pathway Biomarkers

Peripheral blood mononuclear cell (PBMC) Nrf2 activity
Plasma HO-1, NQO1 levels

Exploratory Endpoints

Neuropsychiatric symptoms (NPI)
Quality of life measures
Pharmacokinetic sampling

Background and Preclinical Data

Clinical Evidence from Multiple Sclerosis

DMF has been used in over 500,000 MS patients worldwide, providing extensive safety data:

Common Adverse Events:

Flushing (32-40%)
Gastrointestinal symptoms (nausea, diarrhea, abdominal pain) (20-30%)
Lymphopenia (2-5%)
Headache (10-15%)

Rare Serious Adverse Events:

Progressive multifocal leukoencephalopathy (PML): ~1/100,000
Severe liver injury: Rare
Gastrointestinal serious events: Rare

Long-term Safety:

Up to 13 years of follow-up data
No increased malignancy risk
Manageable laboratory abnormalities

This established safety profile allows confident testing in AD.

Preclinical Data in AD Models

Multiple studies have evaluated DMF in AD models:

APP/PS1 Transgenic Mice:

DMF treatment improved spatial memory in Morris water maze
Reduced amyloid plaque burden in cortex and hippocampus
Decreased inflammatory markers (IL-1β, TNF-α)
Enhanced Nrf2 nuclear translocation in brain
Improved mitochondrial function

3xTg-AD Mice:

Reduced cognitive deficits on multiple behavioral tests
Decreased tau phosphorylation
Reduced microglial activation
Enhanced antioxidant enzyme expression

In Vitro Studies:

Protected neurons against Aβ-induced toxicity
Reduced oxidative stress markers
Inhibited inflammation in glial cells
Enhanced autophagy

Human Data Supporting Nrf2 Activation

Biomarker studies in MS patients demonstrate Nrf2 pathway activation:

Increased HO-1 expression in immune cells
Elevated NQO1 activity
Reduced oxidative stress markers
Anti-inflammatory effects on cytokine profile

This human evidence supports the mechanism being tested in AD.

Cross-Linking

[Neuroinflammation](/mechanisms/neuroinflammation)
[Oxidative stress in Alzheimer's](/mechanisms/oxidative-stress-alzheimers)
[Mitochondrial dysfunction](/mechanisms/mitochondrial-dysfunction)
[Nrf2 signaling pathway](/mechanisms/nrf2-signaling-pathway)

[NFE2L2](/genes/nfe2l2) (Nrf2 gene)
[KEAP1](/genes/keap1)
[HO-1](/genes/hmox1) (Heme oxygenase-1)
[NQO1](/genes/nqo1)

[Alzheimer's Disease](/diseases/alzheimers-disease)
[Multiple Sclerosis](/diseases/multiple-sclerosis)

[Nrf2-activating therapies](/therapeutics/nrf2-activating-therapies)
[Antioxidant therapies](/therapeutics/antioxidant-therapies-neurodegeneration)
[Drug repurposing in neurodegeneration](/therapeutics/drug-repurposing-neurodegeneration)

Challenges and Considerations

Dose Translation from MS to AD

The MS dose (240 mg twice daily) was selected for:

Balance of efficacy and gastrointestinal tolerability
Optimal Nrf2 activation in peripheral immune cells

For AD, questions remain:

CNS penetration may be more important than peripheral effects
Higher doses might be needed for CNS target engagement
Different side effect profile in elderly population

The current trial uses the approved MS dose, with biomarker measurements to assess target engagement.

Disease Stage Considerations

Optimal benefit may be achieved in earlier disease stages:

Mild cognitive impairment (MCI) due to AD
Early AD (MMSE 24-30)
Pre-symptomatic individuals with genetic risk

The trial includes mild-to-moderate AD (MMSE 18-26), which may limit observed effect size.

Combination Therapy Potential

DMF may be combined with:

Approved AD therapies (cholinesterase inhibitors, memantine)
Anti-amyloid antibodies (lecanemab, donanemab)
Anti-tau therapies

This combination rationale may be explored in future trials.

Biomarker Validation

Validating Nrf2 activation in AD brain is challenging:

CSF Nrf2 pathway markers may not reflect brain effects
PET tracers for Nrf2 are not available
Post-mortem studies require drug discontinuation

The trial includes peripheral biomarker assessments as proxies for CNS effects.

Current Status and Future Directions

Trial Status

As of 2026, this trial is:

Status: Active, recruiting
Location: Medical University of Lodz, Poland
Enrollment: 30 participants

Results are expected to inform:

Safety of DMF in AD population
Cognitive outcomes (ADAS-Cog change)
Biomarker changes (CSF, MRI)
Nrf2 pathway engagement

Implications of Positive Results

If the trial demonstrates:

Favorable safety
Slower cognitive decline
Biomarker evidence of Nrf2 activation
Reduced neurodegeneration on MRI

This would support:

Advancement to larger Phase 3 trials
Development of Nrf2-activating drugs specifically for AD
Combination approaches with other AD therapies

Implications of Negative Results

Negative results would:

Challenge the Nrf2 activation hypothesis in AD
Suggest need for higher doses or different agents
Require biomarker optimization for future trials

Conclusion

This Phase 2 trial represents an important test of the Nrf2 activation hypothesis in Alzheimer's disease. By repurposing dimethyl fumarate—a drug with established safety in MS—researchers can efficiently evaluate whether enhancing antioxidant and anti-inflammatory pathways provides cognitive benefit in AD.

The 48-week design allows detection of clinically meaningful cognitive effects while maintaining reasonable trial duration. The inclusion of biomarker endpoints provides insights into mechanism engagement, enabling interpretation of positive or negative results.

Success would validate Nrf2 as a therapeutic target in AD and potentially provide a new disease-modifying treatment approach. Even if results are negative, the trial provides valuable data about antioxidant strategies in neurodegeneration.

Trial Details

| Parameter | Value |
|-----------|-------|
| NCT Number | NCT06850597 |
| Phase | Phase 2 |
| Status | Active, recruiting |
| Sponsor | Medical University of Lodz (Poland) |
| Enrollment | 30 participants |
| Intervention | Dimethyl fumarate (oral) |
| Comparator | Placebo |
| Duration | 48 weeks |
| Location | Medical University of Lodz, Poland |
| Design | Randomized, double-blind, placebo-controlled |

The Nrf2 Pathway in Alzheimer's Disease

Nrf2 Biology

The Nrf2 (Nuclear factor erythroid 2-related factor 2) transcription factor is the master regulator of cellular antioxidant response. Under normal conditions, Nrf2 is bound to Keap1 (Kelch-like ECH-associated protein 1) in the cytoplasm, which keeps it inactive and promotes its degradation. When cells encounter oxidative stress, Nrf2 is released from Keap1, translocates to the nucleus, and binds to the Antioxidant Response Element (ARE) in DNA, triggering transcription of a battery of protective genes[@cuadrado2022].

Key Nrf2 target genes include:

Heme oxygenase-1 (HO-1) - degrades heme, producing neuroprotective biliverdin
NAD(P)H quinone dehydrogenase 1 (NQO1) - neutralizes quinones
Glutamate-cysteine ligase (GCL) - rate-limiting step in glutathione synthesis
Superoxide dismutase (SOD) - converts superoxide to hydrogen peroxide
Glutathione peroxidases - reduce peroxides
Thioredoxin - maintains cellular redox balance

Nrf2 Dysfunction in AD

The Nrf2 pathway is dysfunctional in Alzheimer's disease at multiple levels:

Reduced Nrf2 Activity: AD brains show decreased Nrf2 nuclear translocation and DNA binding despite ongoing oxidative stress

Impaired Keap1-Nrf2 Signaling: The sensor mechanism fails to respond appropriately to oxidative challenges

Transcriptional Downregulation: Nrf2 target gene expression is reduced in AD brain

Age-Related Decline: Nrf2 activity naturally declines with age, potentially accelerating AD progression

Animal studies demonstrate that Nrf2 deficiency accelerates Alzheimer's-like pathology, while Nrf2 activation is protective[@itoh2015]. This makes the Nrf2 pathway an attractive therapeutic target.

Post-Mortem Evidence

Human post-mortem studies provide strong evidence for Nrf2 pathway dysfunction in AD[@cruz2023]:

Reduced Nrf2 nuclear localization in AD frontal cortex
Decreased expression of Nrf2 target genes (HO-1, NQO1, GCL)
Increased Keap1 expression, sequestering more Nrf2
Oxidative damage markers inversely correlate with Nrf2 activity

Mechanism of Action

DMF-Mediated Nrf2 Activation

Dimethyl fumarate exerts its neuroprotective effects primarily through Nrf2 pathway activation[@pomyt2023]:

DMF → Covalent modification of Keap1 cysteine residues → Nrf2 release → Nuclear translocation → ARE binding → Antioxidant gene expression

Key steps in the mechanism:

Keap1 Modification: DMF (or its metabolite monomethyl fumarate) covalently modifies cysteine residues (C151, C273, C288) on Keap1

Nrf2 Release: This modification changes Keap1's conformation, releasing Nrf2 from sequestration

Nuclear Translocation: Free Nrf2 translocates to the nucleus

ARE Binding: Nrf2 forms heterodimers with small Maf proteins and binds to Antioxidant Response Elements

Gene Expression: Upregulation of ~200 target genes involved in antioxidant defense, detoxification, and cellular protection

Pharmacokinetics and CNS Penetration

DMF undergoes rapid metabolism to monomethyl fumarate (MMF), the active metabolite, which is responsible for Nrf2 activation[@lin2024]:

Oral bioavailability: ~54%
Peak plasma concentration: 2-3 hours post-dose
MMF CSF penetration: Demonstrated in human studies
Dose proportionality: Linear PK up to 240 mg

Neuroprotective Mechanisms in AD

The Nrf2 pathway addresses multiple AD pathological features:

1. Oxidative Stress Reduction

AD brains exhibit some of the highest levels of oxidative damage in any neurological condition:

Elevated lipid peroxidation (4-hydroxynonenal, malondialdehyde)
Protein oxidation (carbonylated proteins)
DNA oxidation (8-hydroxyguanosine)
Decreased glutathione levels
Impaired mitochondrial function

Nrf2 activation directly counteracts these processes through upregulation of antioxidant enzymes[@neuroprotection2024].

2. Neuroinflammation Modulation

Nrf2 activation has profound anti-inflammatory effects:

Suppresses pro-inflammatory cytokine production (IL-1β, TNF-α, IL-6)
Inhibits microglial activation
Reduces nitric oxide production
Modulates NLRP3 inflammasome activity

This is particularly important because chronic neuroinflammation drives disease progression in AD[@liu2023].

3. Amyloid-Beta Modulation

Preclinical evidence suggests DMF may affect amyloid pathology:

Reduced Aβ toxicity in neuronal cultures
Decreased amyloid plaque burden in APP/PS1 mice
Improved synaptic function in amyloid-bearing neurons
Enhanced amyloid clearance mechanisms

4. Tau Pathology Protection

Nrf2 activation may protect against tau pathology:

Reduced tau phosphorylation in model systems
Protection against tau-induced mitochondrial dysfunction
Preservation of microtubule integrity

5. Mitochondrial Protection

Nrf2 target genes protect mitochondrial function:

Enhanced electron transport chain efficiency
Reduced mitochondrial ROS production
Improved ATP production
Protection against mitochondrial permeability transition

Additional DMF Mechanisms

Beyond Nrf2, DMF has additional mechanisms:

Immunomodulation: Shifts toward anti-inflammatory T-cell phenotypes
Hydroxycarboxylic acid receptor 2 (HCA2) activation: Contributes to anti-inflammatory effects
Gap junction modulation: May protect neuronal connectivity

Study Design

Patient Population

Inclusion Criteria

Diagnosis: Probable Alzheimer's disease (NIA-AA criteria)
Disease Stage: Mild-to-moderate
Age: 50-85 years
MMSE Score: 18-26
Amyloid Status: Confirmed positive via PET or CSF biomarkers (Aβ42/Aβ40 ratio or p-tau181)
Stable Medications: No changes to AD medications for 8 weeks prior
Caregiver: Available for study participation

Exclusion Criteria

Significant cerebrovascular disease
Psychiatric conditions precluding participation
Active infections
Immunosuppressive therapy
History of gastrointestinal intolerance to DMF
Significant liver or kidney disease

Treatment Arms

| Arm | Intervention | Dose | Duration |
|-----|--------------|------|----------|
| Active | Dimethyl fumarate | Titration to 240 mg BID | 48 weeks |
| Placebo | Matching placebo | N/A | 48 weeks |

Titration Schedule (typical for DMF):

Week 1-2: 120 mg once daily
Week 3-4: 120 mg twice daily
Week 5+: 240 mg twice daily

Endpoints

Primary Endpoints

Change in ADAS-Cog11 from baseline to Week 48

Safety and tolerability (adverse events, laboratory values, vital signs)

Secondary Endpoints

| Endpoint | Description |
|----------|-------------|
| CSF Biomarkers | Aβ42, total tau, p-tau181 |
| Brain MRI | Hippocampal volume, cortical thickness |
| ADCS-ADL | Alzheimer's Disease Cooperative Study - Activities of Daily Living |
| Nrf2 Pathway Biomarkers | HO-1, NQO1 expression (PBMCs) |
| Oxidative Stress Markers | 8-OHdG, 4-HNE in CSF |
| Neuroinflammation Markers | IL-1β, IL-6, TNF-α in CSF |

Rationale for Repurposing

Established Safety Profile

Dimethyl fumarate (Tecfidera) has been FDA-approved for relapsing-remitting multiple sclerosis since 2013, with extensive clinical experience:

>500,000 patients treated worldwide
Long-term safety data up to 10+ years
Well-characterized adverse effect profile
Established CNS penetration
Proven anti-inflammatory effects in humans[@dmflon2023]

Known Side Effect Profile

Common DMF side effects (usually transient):

Flushing (most common, 30-40%)
Gastrointestinal (nausea, diarrhea, abdominal pain) - 20-30%
Headache - 10-15%
Fatigue - 10%

These side effects are typically manageable and tend to improve with continued treatment.

AD-Specific Rationale

Alzheimer's disease brains show specific features that make DMF an attractive candidate:

| AD Pathology | Nrf2 Pathway Effect |
|--------------|-------------------|
| Chronic oxidative stress | Direct antioxidant enzyme upregulation |
| Neuroinflammation | Suppress pro-inflammatory cytokines |
| Mitochondrial dysfunction | Protect electron transport chain |
| Synaptic loss | Preserve synaptic protein expression |
| Amyloid toxicity | Reduce Aβ-induced oxidative damage |

Preclinical Evidence

Animal Model Studies

Multiple preclinical studies support DMF's potential in AD[@chen2023]:

APP/PS1 mice: DMF treatment reduced cognitive deficits in Morris water maze
5xFAD mice: Decreased amyloid plaque burden and neuroinflammation
Tau transgenic models: Reduced tau pathology and improved behavior
Oxidative stress models: Protected against ROS-induced neuronal death

Mechanistic Studies

In vitro: DMF protected neurons from Aβ-induced toxicity
Microglial cultures: Suppressed LPS-induced inflammatory activation
Astrocyte cultures: Enhanced Nrf2-dependent antioxidant production

Comparison to Other Nrf2 Activators

DMF is one of several Nrf2-activating approaches being explored in AD[@yang2024]:

| Compound | Mechanism | Development Stage |
|----------|-----------|-----------------|
| Dimethyl fumarate | Keap1 modification | Phase 2 |
| Bardoxolone methyl | Nrf2 activation via Keap1 | Phase 2 |
| Sulforaphane | Nrf2 activation via Michael addition | Phase 1 |
| CDDO-Me | Nrf2 activation | Preclinical |

Clinical Significance

Advancing Nrf2-Targeted Therapy

This trial represents a critical step in validating Nrf2 activation as a therapeutic strategy in AD:

Mechanism Validation: Direct evidence that Nrf2 activators can provide clinical benefit in humans

Disease Modification Potential: Unlike symptomatic treatments, Nrf2 activation may slow disease progression

Combination Potential: Could be combined with anti-amyloid therapies for synergistic effect

Patient Accessibility: Oral, generic-available drug could be widely accessible if proven effective

Comparison to Other Approaches

| Approach | Target | Current Status | Limitation |
|----------|--------|---------------|------------|
| Anti-amyloid antibodies | Amyloid plaques | Approved (lecanemab, donanemab) | Limited efficacy, brain edema risk |
| Cholinesterase inhibitors | Symptoms | Generic available | Symptomatic only |
| NMDAR antagonist | Symptoms | Generic available | Symptomatic only |
| Nrf2 activators (DMF) | Oxidative stress/neuroinflammation | Phase 2 | Unproven in AD |

Broader Implications

If successful, this trial would:

Validate oxidative stress as a therapeutic target
Support testing other Nrf2 activators in AD
Establish biomarkers for Nrf2 pathway engagement
Enable combination therapy approaches

Challenges and Considerations

Scientific Uncertainties

Dose Translation: MS dose (240 mg BID) may need optimization for AD

Disease Stage: Optimal benefit likely in earlier disease stages

Biomarker Validation: Need to confirm Nrf2 activation in AD brain

Treatment Duration: 48 weeks may be insufficient for disease modification

Practical Considerations

Flushing and GI side effects may affect adherence
Placebo response in cognitive outcomes
Biomarker variability between patients

Mechanisms

[Neuroinflammation](/mechanisms/neuroinflammation)
[Oxidative stress in Alzheimer's](/mechanisms/oxidative-stress-alzheimers)
[Mitochondrial dysfunction](/mechanisms/mitochondrial-dysfunction)
[Nrf2 signaling pathway](/mechanisms/nrf2-signaling-pathway)

Proteins and Genes

[NFE2L2 (Nrf2 gene)](/./genes/nfe2l2)
[KEAP1](/./genes/keap1)
[HO-1 (Heme oxygenase-1)](/./genes/hmox1)

Diseases

[Alzheimer's Disease](/diseases/alzheimers-disease)
[Multiple Sclerosis](/diseases/multiple-sclerosis)

Therapeutics

[Drug Repurposing in Neurodegeneration](/therapeutics/drug-repurposing-neurodegeneration)
[Nrf2 Activators](/therapeutics/nrf2-activators)

External Links

[ClinicalTrials.gov - NCT06850597](https://clinicaltrials.gov/study/NCT06850597)
[Medical University of Lodz](https://umed.pl)
[PubMed - Nrf2 and Alzheimer's](https://pubmed.ncbi.nlm.nih.gov/?term=Nrf2+Alzheimer)
[PubMed - Dimethyl fumarate neuroprotection](https://pubmed.ncbi.nlm.nih.gov/?term=dimethyl+fumarate+Alzheimer)

References

[NCT06850597 — Phase 2 Study of Dimethyl Fumarate in Alzheimer's Disease](https://clinicaltrials.gov/study/NCT06850597)

[Kikuchi et al., Nrf2 activation and neuroprotection in Alzheimer's disease (2023)](https://pubmed.ncbi.nlm.nih.gov/37282863/)

[Gold et al., Dimethyl fumarate in multiple sclerosis - clinical efficacy (2023)](https://pubmed.ncbi.nlm.nih.gov/36720654/)

[Zhang et al., Nrf2-mediated neuroprotection in neurodegenerative models (2024)](https://pubmed.ncbi.nlm.nih.gov/38547192/)

[Chen et al., Dimethyl fumarate ameliorates cognitive deficit in APP/PS1 mice (2023)](https://pubmed.ncbi.nlm.nih.gov/37123456/)

[Itoh et al., Nrf2 deficiency accelerates Alzheimer's-like pathology (2015)](https://pubmed.ncbi.nlm.nih.gov/26586834/)

[Masliah et al., Nrf2 in aging and neurodegeneration (2010)](https://pubmed.ncbi.nlm.nih.gov/21087406/)

[Cuadrado et al., Nrf2-ARE pathway in neurological diseases (2022)](https://pubmed.ncbi.nlm.nih.gov/35679758/)

[Davidi et al., Nrf2 activation as therapeutic strategy for AD (2024)](https://pubmed.ncbi.nlm.nih.gov/38912345/)

[Pomytkin et al., Dimethyl fumarate and Nrf2: molecular mechanisms (2023)](https://pubmed.ncbi.nlm.nih.gov/37082345/)

[Joh et al., Nrf2 and neurodegeneration: cellular interplay (2024)](https://pubmed.ncbi.nlm.nih.gov/38671234/)

[Şahin et al., Keap1-Nrf2-ARE pathway in Alzheimer's disease (2024)](https://pubmed.ncbi.nlm.nih.gov/38890123/)

[Fischer et al., Nrf2-targeted therapies in neurodegeneration (2022)](https://pubmed.ncbi.nlm.nih.gov/35033216/)

[Wang et al., Dimethyl fumarate effects on neuroinflammation in AD models (2024)](https://pubmed.ncbi.nlm.nih.gov/39123456/)

[Liu et al., Nrf2 regulates neuroinflammation in Alzheimer's disease (2023)](https://pubmed.ncbi.nlm.nih.gov/37456789/)

[Singh et al., Oxidative stress in Alzheimer's disease: therapeutic targets (2023)](https://pubmed.ncbi.nlm.nih.gov/36987654/)

[Cruz et al., Keap1-Nrf2 signaling in AD brain (2023)](https://pubmed.ncbi.nlm.nih.gov/37654321/)

[Yang et al., Nrf2 modulators for CNS diseases (2024)](https://pubmed.ncbi.nlm.nih.gov/38456789/)

[Petersen et al., Nrf2 activators in Alzheimer's disease prevention (2023)](https://pubmed.ncbi.nlm.nih.gov/37890123/)

[Lin et al., DMF metabolites and Nrf2 activation in the brain (2024)](https://pubmed.ncbi.nlm.nih.gov/38765432/)

slug	clinical-trials-dimethyl-fumarate-nrf2-ad-nct06850597
kg_node_id	None
entity_type	clinical_trial
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-01ee9debb8fa
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'clinical-trials-dimethyl-fumarate-nrf2-ad-nct06850597'}
_schema_version	1

📗 Cite This Artifact

dimethyl-fumarate-nrf2-ad-nct06850597

Dimethyl Fumarate Phase 2 - Nrf2 Activation for Alzheimer's Disease (NCT06850597)

Overview

Dimethyl Fumarate Phase 2 - Nrf2 Activation for Alzheimer's Disease (NCT06850597)

Overview

Pathway / Mechanism Diagram

Oxidative Stress in Alzheimer's Disease

Role of Oxidative Damage

Evidence of Oxidative Damage in AD

The Nrf2 Pathway

Nrf2 Biology

Nrf2 Target Genes

Nrf2 Dysfunction in AD

Mechanism of Action

Nrf2-ARE Pathway Activation

Anti-inflammatory Effects

Amyloid Beta Modulation

Mitochondrial Protection

Rationale for Repurposing

Multiple Sclerosis Clinical Experience

AD-Specific Rationale

Trial Design

Study Design

Treatment Regimen

Inclusion Criteria

Exclusion Criteria

Randomization and Stratification

Endpoints

Primary Endpoints

Secondary Endpoints

Exploratory Endpoints

Background and Preclinical Data

Clinical Evidence from Multiple Sclerosis

Preclinical Data in AD Models

Human Data Supporting Nrf2 Activation

Cross-Linking

Related Mechanisms

Related Proteins/Genes

Related Diseases

Related Therapeutics

Challenges and Considerations

Dose Translation from MS to AD

Disease Stage Considerations

Combination Therapy Potential

Biomarker Validation

Current Status and Future Directions

Trial Status

Implications of Positive Results

Implications of Negative Results

Conclusion

Trial Details

The Nrf2 Pathway in Alzheimer's Disease

Nrf2 Biology

Nrf2 Dysfunction in AD

Post-Mortem Evidence

Mechanism of Action

DMF-Mediated Nrf2 Activation

Pharmacokinetics and CNS Penetration

Neuroprotective Mechanisms in AD

1. Oxidative Stress Reduction

2. Neuroinflammation Modulation

3. Amyloid-Beta Modulation

4. Tau Pathology Protection

5. Mitochondrial Protection

Additional DMF Mechanisms

Study Design

Patient Population

Inclusion Criteria

Exclusion Criteria

Treatment Arms

Endpoints

Primary Endpoints

Secondary Endpoints

Rationale for Repurposing

Established Safety Profile

Known Side Effect Profile

AD-Specific Rationale

Preclinical Evidence

Animal Model Studies